reglab/housing_qa huggingface dataset:
NH Rev Stat § 126-Z:1 (2021)
2021 New Hampshire Revised Statutes|Title X - Public Health|Title 126-Z - Terminal Patients' Right to Try Act|Section 126-Z:1 - Definitions.

    126-Z:1 Definitions. –||In this chapter:||I. "Eligible patient" means a person to whom all of the following apply:||(a) The person has a terminal illness as determined by the person's physician and a consulting physician.||(b) The person's physician has determined that the person has no comparable or satisfactory United States Food and Drug Administration (FDA) approved treatment options available to diagnose, monitor, or treat the disease or condition involved and that the probable risk to the person from the investigational drug, biological product, or device is not greater than the probable risk from the disease or condition.||(c) The person has received a prescription or recommendation from the person's physician for an investigational drug, biological product, or device.||(d) The person has given written informed consent for the use of the investigational drug, biological product, or device or, if the patient is a minor or lacks the mental capacity to provide informed consent, a parent or legal guardian has given written informed consent on the patient's behalf.||(e) The person has documentation from the person's physician that the person has met the requirements of this paragraph.||II. "Investigational drug, biological product, or device" means a drug, biological product, or device that has successfully completed phase one of a clinical trial, but has not been approved for general use by the FDA and remains under investigation in a clinical trial.||III. "Physician" means the licensed physician who is providing medical care or treatment to the eligible patient for the terminal illness.||IV. "Terminal illness" means a disease that, without life-sustaining procedures, will result in death in the near future or a state of permanent unconsciousness from which recovery is unlikely.|||Source. 2016, 206:2, eff. June 6, 2016.|
NH Rev Stat § 126-Z:2 (2021)
2021 New Hampshire Revised Statutes|Title X - Public Health|Title 126-Z - Terminal Patients' Right to Try Act|Section 126-Z:2 - Availability of Investigational Drugs, Biological Products, or Devices; Costs; Coverage.

    126-Z:2 Availability of Investigational Drugs, Biological Products, or Devices;  Costs;  Coverage. –||I. A manufacturer of an investigational drug, biological product, or device may make available an investigational drug, biological product, or device to eligible patients pursuant to this chapter. A manufacturer may:||(a) Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation.||(b) Require an eligible patient to pay the costs of or associated with the manufacture of the investigational drug, biological product, or device.||(c) Require an eligible patient to participate in data collection relating to the use of the investigational drug, biological product, or device.||II. This chapter shall not require a health care insurer or any state agency to provide coverage for the cost of any investigational drug, biological product, or device.||III. Nothing in this chapter shall require the manufacturer of an investigational drug, biological product, or device to include an eligible patient in a particular clinical trial or study.|||Source. 2016, 206:2, eff. June 6, 2016.|
NH Rev Stat § 126-Z:3 (2021)
2021 New Hampshire Revised Statutes|Title X - Public Health|Title 126-Z - Terminal Patients' Right to Try Act|Section 126-Z:3 - Liability of Physician; Facility.

    126-Z:3 Liability of Physician;  Facility. –||I. Notwithstanding any provision of law to the contrary, the board of medicine shall not revoke, fail to renew, or take any other action against a physician's license issued pursuant to RSA 329 based solely on a physician's recommendation to an eligible patient regarding or prescription for or treatment with an investigational drug, biological product, or device.||II. Notwithstanding any provision of law to the contrary, the department of health and human services shall not take action against a facility licensed under RSA 151 based solely on the institution's participation in the treatment or use of an investigational drug, biological product, or device under this chapter.|||Source. 2016, 206:2, eff. June 6, 2016.|
NH Rev Stat § 126-Z:4 (2021)
2021 New Hampshire Revised Statutes|Title X - Public Health|Title 126-Z - Terminal Patients' Right to Try Act|Section 126-Z:4 - Private Cause of Action.

    126-Z:4 Private Cause of Action. –||Nothing in this chapter shall be construed to create a private cause of action against a manufacturer of an investigational drug, biological product, or device or against any other person or entity involved in the care of an eligible patient using the investigational drug, biological product, or device for any harm done to the eligible patient resulting from the investigational drug, biological product, or device, if the manufacturer or other person or entity is complying in good faith with the terms of this chapter and has exercised reasonable care.|||Source. 2016, 206:2, eff. June 6, 2016.|
NH Rev Stat § 126-Z:5 (2021)
2021 New Hampshire Revised Statutes|Title X - Public Health|Title 126-Z - Terminal Patients' Right to Try Act|Section 126-Z:5 - Severability.

    126-Z:5 Severability. –||If any provision of this chapter, or the application thereof to any person or circumstance is held invalid, the invalidity does not affect the other provisions or applications of the chapter which can be given effect without the invalid provisions or applications and to this end the provisions of this chapter are severable.|||Source. 2016, 206:2, eff. June 6, 2016.|
NH Rev Stat § 126-AA:1 (2021)
2021 New Hampshire Revised Statutes|Title X - Public Health|Title 126-AA - New Hampshire Granite Advantage Health Care Program|Section 126-AA:1 - Definitions.

[RSA 126-AA:1 repealed by 2018, 342:24, III, effective December 31, 2023.]|    126-AA:1 Definitions. –||In this chapter:||I. "Commissioner" means the commissioner of the department of health and human services.||II. "Department" means the department of health and human services.||III. "Fund" means the New Hampshire granite advantage health care trust fund.||IV. "Program" means the New Hampshire granite advantage health care program.||V. "Remainder amount" means, for the 6-month period between January 1, 2019 and June 30, 2019 and for each single identified fiscal year thereafter for any authorized period of the granite advantage health care program, the cost of the program, including administrative costs attributable to the program, minus the following:||(a) The amount of revenue transferred from the alcohol abuse prevention and treatment fund pursuant to RSA 176-A:1, IV;||(b) All federal reimbursement for the program that period or fiscal year, including federal reimbursement for administrative costs related to the program;||(c) Any surplus funds generated as a result of the managed care organizations managing the cost of their services below the minimum medical loss ratio established by the commissioner for the managed care program beginning on July 1, 2019 and thereafter; and||(d) Taxes attributable to premiums written for medical and other medical related services for the newly eligible Medicaid population as provided for under this chapter, consistent with RSA 400-A:32, III(b).|||Source. 2018, 342:1, eff. June 28, 2018.|
NH Rev Stat § 126-AA:5 (2021)
2021 New Hampshire Revised Statutes|Title X - Public Health|Title 126-AA - New Hampshire Granite Advantage Health Care Program|Section 126-AA:5 - Evaluation Report Required.

[RSA 126-AA:5 repealed by 2018, 342:24, III, effective December 31, 2023.]|    126-AA:5 Evaluation Report Required. –||I. The program shall employ an outcome-based evaluation of its Medicaid program annually to:||(a) Provide accountability to patients and the overall program.||(b) Ensure that patients are making informed decisions in carrying out health care choices and utilizing the most appropriate level of care.||(c) Ensure that the use of incentives, the loss of incentives, cost transparency, and reference based pricing have been effective in lowering costs, while maintaining both quality and access and considering changes in health parameters.||II. The results of the evaluation conducted under this section shall be in the form of a report to be provided to CMS, the president of the senate, the speaker of the house of representatives, the governor, and the fiscal committee of the general court by December 31 of each year beginning in 2019.|||Source. 2018, 342:1, eff. June 28, 2018.|
NH Rev Stat § 126-BB:1 (2021)
2021 New Hampshire Revised Statutes|Title X - Public Health|Title 126-BB - New Hampshire Prescription Drug Affordability Board|Section 126-BB:1 - Definitions.

    126-BB:1 Definitions. –||In this chapter:||I. "Board" means the New Hampshire prescription drug affordability board.||II. "Brand-name drug" means a prescription drug marketed under a proprietary name or registered trademark name, including a biological product.||III. "Generic drug" means a prescription drug, whether identified by its chemical, proprietary, or nonproprietary name, that is not a brand-name drug and is therapeutically equivalent to a brand-name drug in dosage, safety, strength, method of consumption, quality, performance, and intended use. "Generic drug" includes a biosimilar product.||IV. "Manufacturer" means a manufacturer of prescription drugs that are distributed in the state. A manufacturer excludes a packager, repackager, labeler, and relabeler.||V. "Pricing unit" means the smallest dispensable amount of a prescription drug that could be dispensed.||VI. "Public payor" means any division of state, county, or municipal government that administers a health plan for its employees or an association of state, county, or municipal employers that administers a health plan for its employees.||VII. "Wholesale acquisition cost" means a manufacturer's listed price for sale to a wholesale drug distributor or other entity that purchases a prescription drug directly from the manufacturer, not including any price concessions.|||Source. 2020, 13:5, eff. July 1, 2020.|
NH Rev Stat § 126-BB:4 (2021)
2021 New Hampshire Revised Statutes|Title X - Public Health|Title 126-BB - New Hampshire Prescription Drug Affordability Board|Section 126-BB:4 - Advisory Council.

    126-BB:4 Advisory Council. –||A 12-member advisory council is established to advise the board on establishing annual spending targets pursuant to RSA 126-BB:5, I and determining methods for meeting those spending targets pursuant to RSA 126-BB:5, III. The advisory council shall consist of the following members:||I. The governor, or designee.||II. The commissioner of the department of administrative services, or designee.||III. The commissioner of the department of corrections, or designee.||IV. The commissioner of department of health and human services, or designee.||V. The attorney general, or designee.||VI. The director of the division of risk and benefits, department of administrative services, or designee.||VII. The president of the New Hampshire State Employees Association, or designee.||VIII. The president of the New Hampshire Education Association, or designee.||IX. The executive director of the New Hampshire Municipal Association or designee.||X. The chancellor of the university system of New Hampshire, or designee.||XI. The chancellor of the New Hampshire community college system, or designee.||XII. A representative of consumer interests, appointed by the governor, who shall serve a 3-year term.|||Source. 2020, 13:5, eff. July 1, 2020.|
NH Rev Stat § 126-BB:6 (2021)
2021 New Hampshire Revised Statutes|Title X - Public Health|Title 126-BB - New Hampshire Prescription Drug Affordability Board|Section 126-BB:6 - Rulemaking.

    126-BB:6 Rulemaking. –||The board shall adopt rules under RSA 541-A for the following:||I. Procedures for drug price transparency as required under RSA 126-BB:7.||II. The adoption of all fees under RSA 126-BB:8.||III. Proceedings for assessing civil fines under RSA 126-BB:10.||IV. Any other matter required to implement this chapter.|||Source. 2020, 13:5, eff. July 1, 2020.|
NH Rev Stat § 126-BB:7 (2021)
2021 New Hampshire Revised Statutes|Title X - Public Health|Title 126-BB - New Hampshire Prescription Drug Affordability Board|Section 126-BB:7 - Drug Price Transparency; Non-disclosure Requirements.

    126-BB:7 Drug Price Transparency;  Non-disclosure Requirements. –||I. The board shall develop and implement policies and procedures for its collection, processing, storage, and analysis of clinical, financial, quality restructuring and prescription drug price data for the following purposes:||(a) To use, build, and improve upon and coordinate existing data sources and measurement efforts through the integration of data systems and standardization of concepts.||(b) To coordinate the development of a linked public and private sector information system.||(c) To emphasize data that is useful, relevant, and not duplicative of existing data.||(d) To minimize the burden on those providing data.||(e) To preserve the reliability, accuracy, and integrity of collected data.||II. The board shall adopt rules to ensure that:||(a) Payors, providers, prescription drug manufacturers, wholesale drug distributors, and pharmacy benefits managers file data as required by RSA 126-BB:9.||(b) Users that obtain health data and information from the board safeguard the identification of patients and health care practitioners.||(c) Payors, providers, prescription drug manufacturers, wholesale drug distributors, and pharmacy benefits managers pay all assessments as required by RSA 126-BB:8.||(d)(1) Only the board and employees assigned to the board may access the information received pursuant to this chapter and only for purpose of effectuating the powers and duties granted the board by this chapter. The board shall limit access to any information that it receives pursuant to this chapter to the smallest number of employees and other personnel possible; and all such individuals shall, as a condition of employment, be required to execute non-disclosure agreements under which they are restricted from disclosing any information they may receive in connection with this chapter during their employment term and in perpetuity post-employment.||(2) If the board, its members, employees, or personnel willfully shares or discloses for unauthorized purposes information that is trade secret information, confidential, commercial or proprietary information, or information designated as "confidential" by the owner of the information, the board or the individual who made the unauthorized disclosure may be subject to any penalties available under federal and state laws, including trade secret misappropriation laws, to the extent permitted by law.|||Source. 2020, 13:5, eff. July 1, 2020.|
NH Rev Stat § 126-BB:8 (2021)
2021 New Hampshire Revised Statutes|Title X - Public Health|Title 126-BB - New Hampshire Prescription Drug Affordability Board|Section 126-BB:8 - Funding; Assessment of Fees.

    126-BB:8 Funding;  Assessment of Fees. –||I. The expenses and cost of operation of the board shall be funded by reasonable user fees and assessments determined in rules adopted by the board.||(a) Fees may be charged for the reasonable costs of duplicating, mailing, publishing, and supplies.||(b) Reasonable user fees shall be charged on a sliding scale for the right to access and use the health data and information available from the board. Fees may be charged for services provided to the department on a contractual basis. Fees may be reduced or waived for users that demonstrate a plan to use the data or information in research of general value to the public health or inability to pay the scheduled fees, as provided by rules adopted by the board.||(c) Annual assessments of not less than $100 assessed against the following entities:||(1) Health insurance carriers and health maintenance organizations on the basis of the total annual health care premium.||(2) Third-party administrators.||(3) Health carriers that provide only administrative services for a plan sponsor.||(4) Pharmacy benefits managers that process and pay claims on the basis of claims processed or paid for each plan sponsor.||(d) Health care policies issued for specified disease, accident, injury, hospital indemnity, disability, long-term care or other limited benefit health insurance policies are not subject to assessment under subparagraph (c). For purposes of this paragraph, policies issued for dental services are not considered to be limited benefit health insurance policies.||(e) Annual assessments of not less than $500 assessed by the board against prescription drug manufacturers, wholesale drug distributors, and pharmacy benefits managers.||II. The aggregate level of annual assessments under subparagraphs (c) and (e) shall be an amount sufficient to meet the board's expenditures authorized. The board may waive assessments otherwise due under subparagraphs (c) and (e) when a waiver is determined to be in the interests of the board and the parties to be assessed.|||Source. 2020, 13:5, eff. July 1, 2020.|
NH Rev Stat § 126-BB:10 (2021)
2021 New Hampshire Revised Statutes|Title X - Public Health|Title 126-BB - New Hampshire Prescription Drug Affordability Board|Section 126-BB:10 - Civil Penalties.

    126-BB:10 Civil Penalties. –||When a person or entity that is a health care facility payor, prescription drug manufacturer, wholesale drug distributor, or pharmacy benefits manager violates any requirement of this chapter, that person or entity commits a civil violation for which a fine of not more than $1,000 per day may be imposed. A fine imposed under this paragraph may not exceed $25,000 for any one occurrence.|||Source. 2020, 13:5, eff. July 1, 2020.|
NH Rev Stat § 126-CC:1 (2021)
2021 New Hampshire Revised Statutes|Title X - Public Health|Title 126-CC - Wholesale Prescription Drug Importation Program|Section 126-CC:1 - Definitions.

    126-CC:1 Definitions. –||In this chapter:||I. "Commissioner" means the commissioner of the department of health and human services.||II. "Department" means the department of health and human services.||III. "Program" means the wholesale prescription drug importation program.|||Source. 2020, 13:6, eff. Sept. 14, 2020.|
NH Rev Stat § 126-CC:2 (2021)
2021 New Hampshire Revised Statutes|Title X - Public Health|Title 126-CC - Wholesale Prescription Drug Importation Program|Section 126-CC:2 - Design of Program: Rulemaking.

    126-CC:2 Design of Program:  Rulemaking. –||I. There is hereby established the wholesale prescription drug importation program, referred to in this chapter as the "program," to provide for the wholesale importation of prescription drugs from Canada by or on behalf of the state.||II. The department, in consultation with appropriate federal and other state agencies and interested parties, shall design the program to comply with the applicable requirements of 21 U.S.C. section 384, including requirements regarding safety and cost savings. The program design shall:||(a) Designate a state agency to become a licensed drug wholesaler or to contract with a licensed drug wholesaler in order to seek federal certification and approval, pursuant to RSA 126-CC:3, to import safe prescription drugs and provide cost savings to consumers in the state.||(b) Use prescription drug suppliers in Canada regulated under the laws of Canada or of one or more Canadian provinces, or both.||(c) Ensure that only prescription drugs that can meet the federal Food and Drug Administration's safety, effectiveness and other standards are imported by or on behalf of the state.||(d) Import only those prescription drugs expected to generate substantial cost savings for consumers in the state.||(e) Ensure that the program complies with the transaction and tracing requirements of 21 U.S.C. sections 360eee and 360eee-1 to the extent feasible and practical prior to imported prescription drugs coming into the possession of the licensed United States drug wholesaler and that the program complies fully with those federal requirements after imported prescription drugs are in the possession of the licensed drug wholesaler.||(f) Prohibit the distribution, dispensing, or sale of imported prescription drugs outside of the state.||(g) Recommend a method to finance the program which will not jeopardize consumer cost savings.||(h) Include an audit function.||III. The commissioner shall adopt rules pursuant to RSA 541-A, to design the program in accordance with this chapter.||IV. The department shall submit a request for approval and certification of the program to the United States Department of Health and Human Services on or before February 1, 2021.|||Source. 2020, 13:6, eff. Sept. 14, 2020.|
NH Rev Stat § 126-CC:3 (2021)
2021 New Hampshire Revised Statutes|Title X - Public Health|Title 126-CC - Wholesale Prescription Drug Importation Program|Section 126-CC:3 - Requirements of Program.

    126-CC:3 Requirements of Program. –||Prior to operating the program, the state agency designated to oversee the program pursuant to this chapter shall:||I. Become a licensed drug wholesaler or enter into a contract with a licensed drug wholesaler in the state.||II. Contract with one or more distributors licensed in the state.||III. Contract with one or more licensed and regulated prescription drug suppliers in Canada.||IV. Seek the appropriate federal approvals, exemptions, or agreements, or a combination thereof, as needed to enable all covered entities enrolled in or eligible for the federal 340B Drug Pricing Program to participate in the program to the fullest extent possible without jeopardizing their eligibility for the 340B Program.||V. Consult with health insurance carriers, employers, pharmacies, pharmacists, health care providers, and consumers.||VI. Develop a registration process for health insurance carriers, pharmacies, and health care providers authorized to prescribe and administer prescription drugs that are willing to participate in the program.||VII. Create a publicly accessible website for listing the prices of prescription drugs to be imported under the program.||VIII. Create an outreach and marketing plan to work with health carriers and provider associations to generate public awareness of the program.||IX. Develop a 2-year audit work plan.||X. Conduct any other activity determined necessary to successfully implement and operate the program.|||Source. 2020, 13:6, eff. Sept. 14, 2020.|
NH Rev Stat § 126-CC:4 (2021)
2021 New Hampshire Revised Statutes|Title X - Public Health|Title 126-CC - Wholesale Prescription Drug Importation Program|Section 126-CC:4 - Annual Report.

    126-CC:4 Annual Report. –||Beginning November 1, 2021, and each November 1 thereafter, the department or other designated state agency shall submit an annual report to the chairperson of the health, human services and elderly affairs committee, the speaker of the house of representatives, the president of the senate, the house clerk, the senate clerk, the governor, and the state library relative to:||I. The prescription drugs included in the program.||II. The number of participating pharmacies, health care providers, and health insurance carriers.||III. The number of prescription drugs dispensed through the program.||IV. The estimated cost savings to consumers, health insurance carriers, employers, and the state during the previous calendar year and to date.||V. Information regarding implementation of the audit work plan and audit findings.||VI. Any other information the department, or other state agency designated to oversee the program pursuant to this chapter, deems relevant.|||Source. 2020, 13:6, eff. Sept. 14, 2020.|